Biogen Aktie - 0R1B

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

277,67

Gebot

0,00

Fragen

0,00

Volumen

3.218

0,00 Tagesbereich 0,00

277,67 52-Wochen-Bereich 277,67

Marktkapitalisierung

40,234B

Handelsende

277,67

Handelsbeginn

Letzte Trade

141.9

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

4.736

Ausgegebene Aktien

144.898.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

17,69

Gewinn pro Aktie (EPS)

8,01

Erlöse

9,84B

Nettogewinn

1,16B

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.biogen.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the Londoner Börse with ticker 0R1B. The last closing price for Biogen was US$277,67. Over the last year, Biogen shares have traded in a share price range of US$ 277,67 to US$ 277,67.

Biogen currently has 144.898.000 shares in issue. The market capitalisation of Biogen is US$40,23 billion. Biogen has a price to earnings ratio (PE ratio) of 17.69.

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease LEQEMBI is the only FDA-approved anti-amyloid...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Dapirolizumab pegol (DZP) met its...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference -New testing method highlights link...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases The collaboration aims to...

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE...

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 The detailed study results confirmed interim...

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB...

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	277.67	277.67	277.67	4344	277.67	DE
4	277.67	277.67	277.67	3048	277.67	DE
12	277.67	277.67	277.67	4736	277.67	DE
26	277.67	277.67	277.67	3477	277.67	DE
52	277.67	277.67	277.67	3635	277.67	DE
156	277.67	277.67	277.67	6052	277.67	DE
260	277.67	277.67	277.67	4823	277.67	DE

0R1B - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is US$ 277,67

How many Biogen shares are in issue?

Biogen has 144.898.000 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is USD 40,23B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of US$ 277,67 to US$ 277,67 during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 17,69

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2,09

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9,84B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1,16B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
NTOGNostra Terra Oil And Gas Company Plc	0,043p (36,51%)	524,2M
BSFABsf Enterprise Plc	3,375p (35,00%)	13,75M
STBSecure Trust Bank Plc	465,00p (33,62%)	929,66k
TIATialis Essential It Plc	26,50p (23,26%)	105,62k
CBGClose Brothers Group Plc	298,40p (21,90%)	4,6M
NTQEnteq Technologies Plc	1,25p (-23,31%)	3,22M
BANKFiinu Plc	8,625p (-15,85%)	21,19M
TIRTiger Royalties And Investments Plc	0,135p (-15,63%)	75,44M
RCGHRc365 Holding Plc	1,80p (-14,29%)	1,7M
INDIIndus Gas Limited	7,80p (-13,33%)	214,66k
NTVONativo Resources Plc	0,0021p (0,00%)	2,71B
PREMPremier African Minerals Limited	0,026p (-3,70%)	623,1M
NTOGNostra Terra Oil And Gas Company Plc	0,043p (36,51%)	524,2M
TRPTower Resources Plc	0,0305p (0,00%)	504,66M
SYMESupply@me Capital Plc	0,003p (-3,23%)	469,16M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Biogen Inc (0R1B)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Biogen Inc

0R1B Neueste Nachrichten

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

0R1B - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Biogen Inc (0R1B) Börsenkurse

Biogen Inc (0R1B)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Biogen Inc

0R1B Neueste Nachrichten

0R1B - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen